Drug Trial Radar · NCT04776187
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
Last checked: Nov 19, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Mar 1, 2021
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- The Central Hospital of Lishui CityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. The study will compare the incidence of adverse events of gadodiamide and gadoteric Acid Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging.
Conditions
- Nephrogenic Fibrosing Dermopathy
Interventions
GadodiamideDrug
Gadodiamide Injection(OMNISCAN™)
Gadoteric Acid Meglumine SaltDrug
Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 60 minutes
- The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 3 months
- The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 6 months
- The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 12 months
- The incidence of various adverse eventsTime frame: From the date of contrast injection to the incidence of adverse events, assessd up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lishui Central Hospital
Lishui, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.